ClinicalTrials.gg
Drug

Tenecteplase clinical trials

Also written TNK-tPA, rhTNK-tPA and Metalyse.

studies test it
96
open now
36
in phase 3
62
first study started
2000

How each study uses Tenecteplase is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Tenecteplase studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
2 Jun 2000 · TNKASE · BLA 103909 (FDA, Drugs@FDA)
European Union
23 Feb 2001 · Metalyse · EMEA/H/C/000306 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Tenecteplase
58
TNK
14
TNKase
7
Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)
6
Intravenous tenecteplase
3

Brand

Metalyse
10

Development codes

TNK-tPA
11
GNR-060
1

Other names

rhTNK-tPA
11

Studies by the year they started

94 studies that test it; most in 2026 (13); 2 more planned to start later

Studies that test Tenecteplase, by start year
YearStudies
20001
20011
20031
20042
20052
20064
20072
20084
20091
20111
20122
20153
20163
20173
20182
20195
20203
20218
20227
20239
20246
202511
202613

By phase

A phase 1/2 study counts in both.

Phase 1
4
Phase 2
25
Phase 3
62
Phase 4
11
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 15 · Other 81

Beijing Tiantan Hospital (12) · General Hospital of Shenyang Military Region (7) · Boehringer Ingelheim (7) · Genentech, Inc. (5) · The First Affiliated Hospital of University of Science and Technology of China (4) · Xuanwu Hospital, Beijing (4) · University of Calgary (4) · Xinqiao Hospital of Chongqing (2)

Often tested with

Tested in the same studies.

Tissue Plasminogen Activator (7) · Minimally Invasive Surgery (1) · Clopidogrel (1) · NONO-42 (1) · Reteplase (1) · Enoxaparin (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 7, 7 in phase 3

Studies that test Tenecteplase, phase 3 first.

Studies

Open first, then newest update. How each study uses Tenecteplase is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 96

See all 96 studies that test Tenecteplase →

As the comparator · 1 — what is tested is compared with Tenecteplase

Codes

What other systems call Tenecteplase · ClinicalTrials.gg INT006808

  • MeSH (NLM) D000077785TenecteplaseConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) WGD229O42WTENECTEPLASEConfirmed FDA, NLM, Wikidata
  • RxNorm 259280Confirmed FDA, Wikidata
  • Wikidata Q1644947tenecteplaseConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C29489TenecteplaseOne source FDA
  • DrugBank DB00031One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.